By nourishing brain cells and improving neural communication ... Clear are backed by traditional use and some clinical research on their individual effects, it’s worth noting that comprehensive ...

India's Clinical Trials: From emerging player to global leader in drug development India's clinical trial industry has surged into the top three globally, driven by regulatory reforms ...

The National Institute of Cardiovascular Diseases (NICVD) is setting up an international-standard clinical trials unit, aimed at promoting medical research and attracting foreign funding. The unit ...

A unit of the Defence Research & Development Organisation has "successfully" carried out field trials of a compact software defined radio (SDR) and a key communication system, reinforcing the ...

AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS. THIS APPR ...

The electronic search that informed most of the clinical questions was limited to randomized phase III clinical trials and meta-analyses. For the special circumstances and populations clinical ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

The Defence Research and Development Organisation (DRDO) has achieved a milestone. It successfully tested its software defined radio and communication system. The trials occurred in Joshimath ...

This is a valuable study on how past sensory experiences shape perception across multiple time scales. Using a behavioural task and reanalysed EEG data, the authors identify two unifying mechanisms ...

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year ...

The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining the potential of XPro™ to slow cognitive decline in early-stage Alzheimer’s disease (AD) by targeting neuroinflammation.